| abstract |
The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin modulator, and (ii) an aldosterone antagonist, for instance a combination comprising (a) glibenclamide, or a structural or functional analogue thereof; and (b) at least one of the following components: (i) exenatide, or a structural or functional analogue thereof, or a pharmaceutically acceptable salt thereof; and (ii) potassium canrenoate, or a structural or functional analogue thereof. Said combinations are suitable for the treatment of stroke and other neurodegenerative disorders and for treating and/or preventing ischemia and/or reperfusion injury in various vital organs, including the brain and the heart. Further aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations according to the invention, and methods of treatment using the same. |